Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes. Issue 4 (18th March 2019)

• Record Type: Journal Article
• Authors: de Santiago, Ines; Yau, Christopher; Heij, Lara; Middleton, Mark R.; Markowetz, Florian; Grabsch, Heike I.; Dustin, Michael L.; Sivakumar, Shivan
• Is Part Of: International journal of cancer. Volume 145:Issue 4(2019)
• Page Start: 1125
• Page End: 1137
• Publication Date: 2019-03-18
• Subjects: pancreatic cancer -- tumour microenvironment -- T cells -- adaptive immunity -- innate immunity -- subtypes; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.32186
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of the highest mortality rates of any cancer type with a 5‐year survival rate of <5%. Recent studies of PDAC have provided several transcriptomic classifications based on separate analyses of individual patient cohorts. There is a need to provide a unified transcriptomic PDAC classification driven by therapeutically relevant biologic rationale to inform future treatment strategies. Here, we used an integrative meta‐analysis of 353 patients from four different studies to derive a PDAC classification based on immunologic parameters. This consensus clustering approach indicated transcriptomic signatures based on immune infiltrate classified as adaptive, innate and immune‐exclusion subtypes. This reveals the existence of microenvironmental interpatient heterogeneity within PDAC and could serve to drive novel therapeutic strategies in PDAC including immune modulation approaches to treating this disease. Abstract : What's new? While several transcriptomic classifications of pancreatic adenocarcinoma (PDAC) have been proposed, a unified classification would be valuable to inform future treatment strategies. Through an integrative meta‐analysis of 353 patients from four different studies, the authors found that the greatest prognostic value in independent cohorts could be achieved through stratification by gene expression signatures associated with tumour‐infiltrating immune cells across different pancreatic cancer subtypes. Recognising the existence of different tumour escape mechanisms (and indeed phenotypes) in pancreatic cancer may guide immunotherapeutic treatment plans and improve patient stratification for maximization of therapeutics.